Molecular basis of ligand recognition and activation of human V2 vasopressin receptor

Fulai Zhou, Chenyu Ye, Xiaomin Ma, Wanchao Yin, Qingtong Zhou, Xinheng He, Xiaokang Zhang, Tristan I. Croll, Dehua Yang, Peiyi Wang, H. Eric Xu, Ming‐Wei Wang, Yi JiangbioRxiv 2021 · DOI

TL;DR

Researchers have determined the near-atomic resolution structure of the human V2 vasopressin receptor (V2R) bound to its natural ligand, arginine vasopressin (AVP), and the Gs protein. This groundbreaking work reveals a unique AVP binding mode and an unconventional activation mechanism, providing a crucial structural template for developing new drugs targeting V2R for conditions like diabetes insipidus.

What Problem Does This Paper Address?

The V2 vasopressin receptor (V2R) is a critical player in regulating water balance in the body and is a key therapeutic target for conditions such as diabetes insipidus, nocturia, and hyponatremia. While its importance is well-established, the precise molecular mechanisms by which AVP, the natural ligand, binds to and activates V2R have remained unclear. Understanding these interactions at a structural level is essential for rational drug design to develop more effective and selective V2R modulators.

Methods

The study employed cryo-electron microscopy (cryo-EM) to determine the high-resolution (2.6 Å) structure of the AVP-V2R-Gs complex. This technique involves freezing a solution of the protein complex and then imaging it with an electron microscope to reconstruct a 3D model. To achieve this, the researchers engineered a mini-Gs protein and utilized a NanoBiT tethering strategy to stabilize the complex for imaging. They also performed alanine mutagenesis to probe the functional significance of specific amino acid residues involved in ligand binding and receptor activation. Molecular docking and MMGBSA calculations were used to explore the binding of other related peptides like oxytocin.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Unique AVP Conformation: AVP adopts a distinct "spoon-like" cyclic conformation due to an intramolecular disulfide bond, which is crucial for its specific recognition by V2R.
  • Ligand-Specific Binding: The binding pocket of V2R is tailored for AVP, with specific hydrogen bond networks and hydrophobic interactions that differentiate it from other related peptides like oxytocin.
  • Unconventional Activation Mechanism: V2R activation by AVP exhibits unique features compared to other Gs-coupled class A GPCRs, including a smaller outward movement of transmembrane helices TM5 and TM6 and a distinct "P-I-F" micro-switch involving polar residues.
  • TM7 Distortion: A unique distortion in TM7 helix, stabilized by a polar interaction with AVP's Tyr2P, plays a role in V2R activation.
  • Diversified Gs Coupling: The V2R-Gs interaction shows a smaller cytoplasmic cavity and a distinct shift of the Gas alpha-5 helix, suggesting a unique Gs coupling mechanism.
  • Disease Mutation Insights: The structural data provides a basis for understanding how mutations in V2R, associated with diseases like nephrogenic diabetes insipidus, affect receptor function.

Key Results

  • The study successfully determined the 2.6 Å resolution cryo-EM structure of the AVP-V2R-Gs complex.
  • Detailed interactions between AVP and V2R were elucidated, highlighting key residues involved in binding and activation.
  • Mutagenesis studies confirmed the critical role of specific residues in AVP-induced cAMP accumulation, a measure of receptor activation.
  • Comparisons with other GPCR structures revealed unique aspects of V2R activation and Gs protein coupling.

Limitations and Future Work

The authors acknowledge that the intracellular loop 3 (ICL3) of V2R, which has been implicated in G protein coupling, was not visible in their structure. They suggest that further structural information, potentially from different complexes or using other techniques, would be needed to fully elucidate its role. The study also provides a structural template for drug design, and future work will likely focus on using this information to develop novel V2R agonists and antagonists with improved selectivity and pharmacokinetic properties. Additionally, further investigation into the complex mechanisms underlying V2R mutation-associated diseases, including impaired intracellular trafficking and abnormal receptor expression, is warranted.

Summary updated

Abstract

Abstract The V2 vasopressin receptor (V2R) is a class A G protein-coupled receptor (GPCR) and plays a vital role in controlling water homeostasis upon stimulation by the natural peptide arginine vasopressin (AVP). Thus, V2R has attracted intense interest as a drug target for diabetes insipidus, nocturia, and hyponatremia. However, how AVP recognizes and activates V2R remains elusive. Here, we report the 2.6 Å resolution structure of V2R bound to AVP and the stimulatory G protein G s , determined by cryo-electron microscopy (cryo-EM). In this complex, AVP presents a unique cyclic conformation formed by an intramolecular disulfide bond and engages the orthosteric binding pocket of V2R in a ligand-specific mode. Comparison of the AVP–V2R–G s complex to previously reported G s -coupled class A GPCRs reveals distinct structural features, including a smaller outward movement of TM5 and TM6 and the concomitant shift of G s protein. Our detailed structural analysis provides a framework for understanding AVP recognition and V2R activation, thereby offering a structural template for drug design targeting V2R.
BibTeX
@misc{zhou2021molecular,
  author = {Fulai Zhou and Chenyu Ye and Xiaomin Ma and Wanchao Yin and Qingtong Zhou and Xinheng He and Xiaokang Zhang and Tristan I. Croll and Dehua Yang and Peiyi Wang and H. Eric Xu and Ming‐Wei Wang and Yi Jiang},
  title = {{Molecular basis of ligand recognition and activation of human V2 vasopressin receptor}},
  year = {2021},
  doi = {10.1101/2021.01.18.427077},
  howpublished = {bioRxiv},
}
Figure